Literature DB >> 9748239

The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates.

N Vu-Dac1, S Chopin-Delannoy, P Gervois, E Bonnelye, G Martin, J C Fruchart, V Laudet, B Staels.   

Abstract

Fibrates are widely used hypolipidemic drugs which activate the nuclear peroxisome proliferator-activated receptor (PPAR) alpha and thereby alter the transcription of genes controlling lipoprotein metabolism. Fibrates influence plasma high density lipoprotein and its major protein, apolipoprotein (apo) A-I, in an opposite manner in man (increase) versus rodents (decrease). In the present study we studied the molecular mechanisms of this species-specific regulation of apoA-I expression by fibrates. In primary rat and human hepatocytes fenofibric acid, respectively, decreased and increased apoA-I mRNA levels. The absence of induction of rat apoA-I gene expression by fibrates is due to 3 nucleotide differences between the rat and the human apoA-I promoter A site, rendering a positive PPAR-response element in the human apoA-I promoter nonfunctional in rats. In contrast, rat, but not human, apoA-I transcription is repressed by the nuclear receptor Rev-erbalpha, which binds to a negative response element adjacent to the TATA box of the rat apoA-I promoter. In rats fibrates increase liver Rev-erbalpha mRNA levels >10-fold. In conclusion, the opposite regulation of rat and human apoA-I gene expression by fibrates is linked to differences in cis-elements in their respective promoters leading to repression by Rev-erbalpha of rat apoA-I and activation by PPARalpha of human apoA-I. Finally, Rev-erbalpha is identified as a novel fibrate target gene, suggesting a role for this nuclear receptor in lipid and lipoprotein metabolism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9748239     DOI: 10.1074/jbc.273.40.25713

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

1.  Classification of a large microarray data set: algorithm comparison and analysis of drug signatures.

Authors:  Georges Natsoulis; Laurent El Ghaoui; Gert R G Lanckriet; Alexander M Tolley; Fabrice Leroy; Shane Dunlea; Barrett P Eynon; Cecelia I Pearson; Stuart Tugendreich; Kurt Jarnagin
Journal:  Genome Res       Date:  2005-05       Impact factor: 9.043

Review 2.  Therapeutic interventions to enhance apolipoprotein A-I-mediated cardioprotection.

Authors:  Michael J Haas; Arshag D Mooradian
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

3.  Fenofibrate Decreases Insulin Clearance and Insulin Secretion to Maintain Insulin Sensitivity.

Authors:  Sadeesh K Ramakrishnan; Lucia Russo; Simona S Ghanem; Payal R Patel; Ana Maria Oyarce; Garrett Heinrich; Sonia M Najjar
Journal:  J Biol Chem       Date:  2016-09-23       Impact factor: 5.157

4.  Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma.

Authors:  Andrew C Li; Christoph J Binder; Alejandra Gutierrez; Kathleen K Brown; Christine R Plotkin; Jennifer W Pattison; Annabel F Valledor; Roger A Davis; Timothy M Willson; Joseph L Witztum; Wulf Palinski; Christopher K Glass
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

5.  Peroxisome proliferator-activated receptor alpha target genes.

Authors:  Maryam Rakhshandehroo; Bianca Knoch; Michael Müller; Sander Kersten
Journal:  PPAR Res       Date:  2010-09-26       Impact factor: 4.964

6.  The Role of PPARα Activation in Liver and Muscle.

Authors:  Lena Burri; G Hege Thoresen; Rolf K Berge
Journal:  PPAR Res       Date:  2010-08-18       Impact factor: 4.964

7.  Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver.

Authors:  Eliete J B Bighetti; Patrícia R Patrício; Andrea C Casquero; Jairo A Berti; Helena C F Oliveira
Journal:  Lipids Health Dis       Date:  2009-11-23       Impact factor: 3.876

8.  Role of Esrrg in the fibrate-mediated regulation of lipid metabolism genes in human ApoA-I transgenic mice.

Authors:  D Sanoudou; A Duka; K Drosatos; K C Hayes; V I Zannis
Journal:  Pharmacogenomics J       Date:  2009-12-01       Impact factor: 3.550

9.  Regulation of bile acid and cholesterol metabolism by PPARs.

Authors:  Tiangang Li; John Y L Chiang
Journal:  PPAR Res       Date:  2009-07-14       Impact factor: 4.964

10.  Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk?

Authors:  Ahmad Aljada; Kshitij Ashwin Shah; Shaker A Mousa
Journal:  PPAR Res       Date:  2009-08-19       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.